| Followers | 48 |
| Posts | 23523 |
| Boards Moderated | 0 |
| Alias Born | 09/16/2012 |
Friday, October 10, 2025 6:29:45 PM
LP and the disciples just forget to tell investors that.🤷♀️
>>However, a potential downside to this form of therapy is that it can create a pro-inflammatory environment within the tumor that can mitigate the impact of the vaccine by creating an immune tolerance instead of an immune response. Dr. Liau and Dr. Prins are now researching how to address this issue, namely by studying the interactions that occur on a local cellular level. They postulate that these micro-interactions are a critical factor in the efficacy of immunotherapies in glioblastoma patients. Additionally, they hope that their research can provide more insight into impactful ways to induce therapeutic anti-tumor immune responses for glioblastoma.)
UCLA Brain SPORE Project 2
Despite these potential setbacks, Dr. Prins is optimistic about immunotherapeutic interventions to treat
glioblastoma. "Immunotherapy is theoretically one of the best new treatments that can target isolated tumor cells before they metastasize elsewhere," said Dr. Prins. "I think immunotherapies are going to be the next new revolution in this cancer therapy."
The other two SPORE projects target different aspects of brain cancer.…
https://hotb.org/wp-content/uploads/2022/05/spore-article-for-donors-4.18.22.pdf
>>However, a potential downside to this form of therapy is that it can create a pro-inflammatory environment within the tumor that can mitigate the impact of the vaccine by creating an immune tolerance instead of an immune response. Dr. Liau and Dr. Prins are now researching how to address this issue, namely by studying the interactions that occur on a local cellular level. They postulate that these micro-interactions are a critical factor in the efficacy of immunotherapies in glioblastoma patients. Additionally, they hope that their research can provide more insight into impactful ways to induce therapeutic anti-tumor immune responses for glioblastoma.)
UCLA Brain SPORE Project 2
Despite these potential setbacks, Dr. Prins is optimistic about immunotherapeutic interventions to treat
glioblastoma. "Immunotherapy is theoretically one of the best new treatments that can target isolated tumor cells before they metastasize elsewhere," said Dr. Prins. "I think immunotherapies are going to be the next new revolution in this cancer therapy."
The other two SPORE projects target different aspects of brain cancer.…
https://hotb.org/wp-content/uploads/2022/05/spore-article-for-donors-4.18.22.pdf
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
